RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2596-2604

  Mack, Philip C ^a   Gandara, David R ^a,c   Bowen, Cai ^a,e   Edelman, Martin J ^c,f   Paglieroni, Teresa ^d   Schnier, Joachim B ^b   Gelmann, Edward P ^a,e   Gumerlock, Paul H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Sacramento Medical Foundation Blood Centers   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 7 HYDROXYSTAUROSPORINE; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA CONTENT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ALKALOIDS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ENZYME INHIBITORS; G1 PHASE; GENES, P53; GENES, RETINOBLASTOMA; GROWTH INHIBITORS; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; STAUROSPORINE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032852874     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Harris, C. C. Structure and function of the p53 tumor suppressor gene: clues for the rational cancer therapeutic strategies. J. Natl. Cancer Inst., 88: 1442-1455, 1996.
2. Ewen, M. E. The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev., 13: 45-66, 1994.
3. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 87: 323-330, 1995.
4. Kato, J. Y., Matsushime, H., Hiebert, S. W., Ewen, M. E., and Sherr, C. J. Direct binding of cyclin D to the retinoblastoma gene product (pRB) and pRB phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev., 7: 331-342, 1993.
5. Sherr, C. J. Mammalian G1 Cyclins. Cell, 73: 1059-1065, 1993.
6. MacLachlan, T. K., Sang, N., and Giordano, A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit. Rev. Eukaryotic Gene Expr., 5: 127-156, 1995.
7. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclinD/CDK4. Nature (Lond.), 366: 704-707, 1993.
8. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
9. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
10. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
11. Kelley, M. J., Nakagawa, K., Steinberg, S. M., Mulshine, J. L., Kamb, A., and Johnson, B. E. Differential inactivation of CDKN2 and RB protein in non-small-cell and small-cell lung cancer cell lines. J. Natl. Cancer Inst., 87: 756-761, 1995.
12. Shimizu, E., Coxon, A., Otterson, G. A., Steinberg, S. M., Kratzke, R. A., Whan Kim, Y., Fedorko, J., Oie, H., Johnson, B. E., Mulshine, J. L., Minna, J. D., Gazdar, A. F., and Kaye, F. J. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene, 9: 2441-2448, 1994.
13. Mitsudomi, T., Steinberg, S. M., Nau, M. M., Carbone, D., D'Amico, D., Bodner, S., Oie, H. K., Linnoila, R. I., Mulshine, J. L., Minna, J. D., and Gazdar, A. F. p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene, 7: 171-180, 1992.
14. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., and Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res., 57: 4888-4892, 1991.
15. Seynaeve, C. M., Stetler-Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., and Worland, P. J. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res., 53: 2081-2086, 1993.
16. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 32: 183-189, 1993.
17. Pollack, I. F., Kawecki, S., and Lazo, J. S. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase inhibitor. J. Neurosurg., 84: 1024-1032, 1996.
18. Bunch, R. T., and Eastman, A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res., 2: 791-797, 1996.
19. Wang, Q., Fan, S., Eastman, A., Worland, P., Sausville, E. A., and O'Connor, P. M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst., 88: 956-965, 1996.
20. Takahashi, I., Kobayashi, E., Asano, K., Yoshida, M., and Nakana, H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J. Antibiot., 40: 1782-1784, 1987.
21. Wang, Q., Worland, P., Clark, J. L., Carlson, B. A., and Sausville, E. A. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ., 6: 927-936, 1995.
22. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Che-mother. Pharmacol., 33: 273-280, 1994.
23. Kawakami, K., Futami, H., Takahara, J., and Yamaguchi, K. UCN-01 7-hydroxyl-staurosporine inhibits kinase activity of cyclin-dependent kinases and reduces phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem. Biophys. Res., 219: 778-793, 1996.
24. Akiyama, T., Yoshida, T., Tsujita, T., Shimizu, M., Mizukami, T., Okabe, M., and Akinaga, S. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of RB and CDK2 proteins as well as induction of CDK inhibitor p21/cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res., 57: 1495-1501, 1997.
25. Gumerlock, P. H., Meyers, F. J., Kokoris, S. P., Wong, G., McCormick, F. P., and deVere White, R. W. RAS enzyme-linked immunoblot assay discriminates p21 species: a technique to dissect gene family expression, Anal. Biochem., 180: 158-168, 1989.
26. Schnier, J. B., Nishi, K., Goodrich, D. W., and Bradbury, E. M. G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc. Natl. Acad. Sci. USA, 93: 5941-5946, 1996.
27. Bowen, C., Spiegel, S., and Gelmann, E. P. Radiation-induced apoptosis mediated by retinoblastoma protein. Cancer Res., 58: 3275-3281, 1998.
28. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 580-585, 1970.
29. Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. Feasibility of drug screening with panels of human tumor lines using a microculture tetrazolium assay. Cancer Res., 48: 589-601, 1988.
30. Deitch, A. D., Law, H., and deVere White, R. W. A stable propidium iodide staining procedure for flow cytometry. J. Histochem. Cytochem., 30: 967-972, 1982.
31. Okamoto, A., Hussain, S. P., Hagiwara, K., Spillare, E. A., Rusin, M. R., Demetrick, D. J., Serrano, M., Hannon, G. J., Shiseki, M., Zariwala, M., Xiong, Y., Beach, D. H., Yokota, J., and Harris, C. C. Mutations in the p161NK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res., 55: 1448-1451, 1995.
32. Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H., and Harris, C. Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045-11049, 1994.
33. Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J., Richards, W., Sugarbaker, D. J., and Rollins, B. J. Reciprocal RB inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res., 55: 505-509, 1995.
34. Chi, S. G., deVere White, R. W., Muenzer, J. T., Gumerlock, P. H. Frequent alterations of CDKN2 (p16ink4a/MTS1) expression in human primary prostate carcinomas. Clin. Cancer Res., 3: 1889-1897, 1997.
35. D'Amico, D., Carbone, D., Mitsudomi, T., Nau, M. M., Fedorko, J., Russell, E., Johnson, B., Buchhagen, D., Bodner, S., Phelps, R., Gazdar, A., and Minna, J. D. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene, 7: 339-346, 1992.
36. Wang, N. P., To, H., Lee, W. H., and Lee, E. Y. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene, 8: 279-288, 1993.
37. 1 arrest at two points: effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells. Cancer Res., 54: 5959-5963, 1994.
38. Nishi, K., Schnier, J. B., and Bradbury, E. M. The accumulation of cyclin-dependent kinase inhibitor p27kip1 is a primary response to staurosporine and independent of G1 cell cycle arrest. Exp. Cell Res., 243: 222-231, 1998.
39. Husain, A., Yan, X-J., Rosales, N., Aghajanian, C., Schwartz, G. K., and Spriggs, D. R. UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II) independent of p53 status. Clin. Cancer Res., 3: 2089-2097, 1997.